1) O'Neill JH, Murray NMF, Newsom-Davis J:The Lambert-Eaton myasthenic syndrome-a review of 50 cases. Brain 1988;111:577-96 2) Titulaer MJ, Wirtz PW, Kuks JB, et al:The Lambert-Eaton myasthenic syndrome 1988-2008:a clinical picture in 97 patients. Neuroimmunology 2008;201:153-8 3) Titulaer MJ, Maddison P, Sont JK, et al:Clinical Dutch-English Lambert-Eaton Myasthenic syndrome(LEMS)tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011;29:902-8 4) Lennon VA, Kryzer TJ, Griesmann GE, et al:Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-74 5) Maddison P:Treatment in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 2012;1275:78-84 6) Skeie GO, Apostolski S, Evoli A, et al:Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902 7) Vedeler CA, Antoine JC, Giometto B, et al:Paraneoplastic neurological syndromes. In:Gilhus NE, Barnes MP, Brainin M (eds), European Handbook of Neurological Management, 2nd ed, Blackwell Publishing Ltd., Oxford, 2011, pp.447-57 8) Newsom-Davis J, Murray NM:Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984;34:480-5